EFFECTIVENESS AND SAFETY OF SOFOSBUVIR AND VELPATASVIR IN HEMODIALYSIS PATIENTS SUFFERING WITH HEPATITIS C INFECTION

by Yasir Mehmood, Muhammad Imran Ashraf, Khadija Mastoor, Adnan Afzal, Zafar Latif Awan
Published 2021-02-01

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

by Melissa J. Barber, Dzintars Gotham, Giten Khwairakpam, Andrew Hill
Published 2020-09-01

In-Vitro and In-Vivo Evaluation of Velpatasvir- Loaded Mesoporous Silica Scaffolds. A Prospective Carrier for Drug Bioavailability Enhancement

by Yasir Mehmood, Ikram Ullah Khan, Yasser Shahzad, Rizwan Ullah Khan, Muhammad Shahid Iqbal, Haseeb Ahmad Khan, Ikrima Khalid, Abid Mehmood Yousaf, Syed Haroon Khalid, Sajid Asghar, Muhammad Asif, Talib Hussain, Shefaat Ullah Shah
Published 2020-03-01

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

by Phunchai Charatcharoenwitthaya, Virasak Wongpaitoon, Piyawat Komolmit, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Teerha Piratvisuth, Theeranun Sanpajit, Chinnavat Sutthivana, Chalermrat Bunchorntavakul, Abhasnee Sobhonslidsuk, Soonthorn Chonprasertsuk, Chotipong Siripipattanamongkol, Supatsri Sethasine, Tawesak Tanwandee, The THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C
Published 2020-03-01

Hepatitis C: A Pharmacological Therapeutic Update

by Sonia Santander Ballestín, David Gómez Martín, Sara Lorente Pérez, María José Luesma Bartolomé
Published 2021-04-01

SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

by Arif Qayyum Khan, Hala Mansoor, Samina Fida, Saba Saif, Javed Iqbal, Muhammad Siddique
Published 2021-02-01

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

by Tang Q, Wei L, Liu X, Hu P
Published 2021-06-01

Multivariate optimization and evaluation of quaternary mixture in bulk and co-formulated dosage forms by central composite design

by Rama Tulasi Jampana, Prameela Rani Avula, Panikumar Durga Anumolu
Published 2021-05-01

Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study

by Alessandra Mangia, Francesco Scaglione, Pierluigi Toniutto, Mario Pirisi, Nicola Coppola, Giovanni Di Perri, Gema Alvarez Nieto, Stefano Calabrese, Candido Hernandez, Valentina Perrone, Luca Degli Esposti, Stefano Fagiuoli
Published 2021-07-01

Two novel UPLC methods utilizing two different analytical columns and different detection approaches for the simultaneous analysis of velpatasvir and sofosbuvir: application to the...

by Moustapha Eid Moustapha, Rania Mohamed El-Gamal, Fathalla Fathalla Belal
Published 2019-09-01

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

by Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor
Published 2020-09-01

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure

by Mir F, Kahveci AS, Ibdah JA, Tahan V
Published 2017-02-01

Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan

by Chen-Hua Liu, Tung-Hung Su, Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao
Published 2020-12-01

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients

by A. Maughan, K. Sadigh, V. Angulo-Diaz, C. Mandimika, M. Villanueva, J. K. Lim, O. Ogbuagu
Published 2019-05-01

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan

by Yu-Ting Huang, Yung-Yu Hsieh, Wei-Ming Chen, Shui-Yi Tung, Kuo-Liang Wei, Chen-Heng Shen, Kao-Chi Chang, Chung-Kuang Lu, Chih-Wei Yen, Sheng-Nan Lu, Chao-Hung Hung, Te-Sheng Chang
Published 2021-06-01

High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55–85

by Annarita Valeria Piazzolla, Giulia Paroni, Francesca Bazzocchi, Mauro Cassese, Antonio Cisternino, Luigi Ciuffreda, Franco Gorgoglione, Leonardo Gorgoglione, Vincenzo Palazzo, Natale Sciannamè, Marco Taurchini, Pasquale Vaira, Giovanna Cocomazzi, Maria Maddalena Squillante, Filippo Aucella, Nicola Cascavilla, Salvatore De Cosmo, Michelantonio Fania, Antonio Greco, Antonio Laborante, Maurizio Leone, Evaristo Maiello, Mauro Salvatori, Lazzaro Di Mauro, Alessandra Mangia
Published 2021-06-01

Hur effektiv och säker är kombinationen av sofosbuvir och velpatasvir mot kronisk hepatit C-infektion

by Rydén, Björn
Published 2017

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study

by Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Makoto Nakamuta, Koichi Takaguchi, Tsunamasa Watanabe, Atsushi Hiraoka, Haruki Uojima, Toru Ishikawa, Motoh Iwasa, Toshifumi Tada, Akito Nozaki, Makoto Chuma, Shinya Fukunishi, Akira Asai, Toru Asano, Chikara Ogawa, Hiroshi Abe, Naoki Hotta, Toshihide Shima, Etsuko Iio, Shigeru Mikami, Yoshihiko Tachi, Shinichi Fujioka, Hironao Okubo, Noritomo Shimada, Joji Tani, Isao Hidaka, Akio Moriya, Kunihiko Tsuji, Takehiro Akahane, Naoki Yamashita, Tomomi Okubo, Taeang Arai, Kiyoshi Morita, Kazuhito Kawata, Yasuhito Tanaka, Takeshi Okanoue, Shin Maeda, Takashi Kumada, Katsuhiko Iwakiri, KTK49 Liver Study Group
Published 2020-09-01

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3

by Muhammad Sarfraz, Arshad Rabbani
Published 2020-03-01

A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofos...

by Kazuo Tarao, Akito Nozaki, Hirokazu Komatsu
Published 2021-04-01